Cart
0

Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_182841
Pages: 232
Feb 2018 | 3981 Views
 
Author's : Garima Chandra and Tenzin Kunsel
Tables: 116
Charts: 51
 

Gene Therapy Market Overview:

Genes are composed of DNA that contains necessary information for making proteins that are vital for the human body to function optimally. Some gene mutations result in these proteins not being made correctly and can lead to genetic disorders. Gene therapy works by repairing, repressing, or replacing dysfunctional genes that cause disease with the aim of reestablishing normal function. Gene therapy is an attractive area for drug development because with the right target and approach, it can address the root cause of a severe disease. For certain disorders where known genetic mutations lead to deficient or non-functional protein production, gene therapy can fix the underlying defect and provide a path to produce the functional protein. The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023.

The increase in funding for R&D activities pertaining to gene therapy and increase in awareness regarding gene therapy are the major factors that drive the market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer can fuel the growth of the gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to hamper the market growth.

Vector Type Segment Review

Based on vector type, it is categorized into viral vector and non-viral vector. Among the vector type, viral vector is the largest contributor toward the market growth. Non-viral vector is anticipated to be a lucrative market due to the technological advancement of these vectors with positive results for these therapies during the preclinical and clinical trials for the treatment of various diseases.

Get more information on this report : Request Sample Pages

Application Segment Review

Based on application, it is categorized into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Viral Oncological disorders is the largest contributor toward the market growth owing to the high prevalence of cancer worldwide and availability of regulatory approved gene therapy for cancer. However, cardiovascular diseases is anticipated to be a lucrative market due to the large number of clinical trials of gene therapy for the treatment of these diseases.

Get more information on this report : Request Sample Pages

Global Gene Therapy Market: Key Geographic Segment

Based on region, the gene therapy market is divided into North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the gene therapy market in 2016, and is expected to retain its dominance throughout the forecast period.

Get more information on this report : Request Sample Pages

The key players operating in the global gene therapy market include Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc., Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica, and NewLink Genetics Corp.

Other prominent players in the value chain include Amgen, Epeius Biotechnologies, Abeona Therapeutics, Sanofi, UniQure, Juno Therapeutics, Adaptimmune, Celgene, and Advantagene.

Key Benefits

  • This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • The global market is comprehensively analyzed with respect to type, method, technology, end user, and region.
  • In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Gene Therapy Market Key Segments:

By Vector Type

  • Viral vector
    • Retroviruses
    • Lentiviruses
    • Adenoviruses
    • Adeno Associated Virus
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Non-viral vector
    • Naked/Plasmid Vectors
    • Gene Gun
    • Electroporation
    • Lipofection
    • Others

By Gene Type

  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth factors
  • Receptors
  • Others

By Application

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Republic of South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Top winning strategies, by year, 2015-2017*
3.2.2.2. Top winning strategies, by development, 2015-2017* (%)
3.2.2.3. Top winning strategies, by company, 2015-2017*

3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. High investment for R&D activities pertaining to gene therapy
3.5.1.2. Increase in prevalence of cancer
3.5.1.3. Growth in awareness regarding gene therapy

3.5.2. Restraints

3.5.2.1. High cost associated with gene therapies
3.5.2.2. Unwanted immune responses

3.5.3. Opportunity

3.5.3.1. Untapped potential for emerging markets

Chapter: 4 GENE THERAPY MARKET, BY VECTOR TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. VIRAL VECTORS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Market size and forecast by country
4.2.5. Adenovirus
4.2.6. Lentivirus
4.2.7. Retrovirus
4.2.8. Adeno-associated virus
4.2.9. Herpes simplex virus
4.2.10. Poxvirus
4.2.11. Vaccinia virus
4.2.12. Others

4.3. NONVIRAL TECHNIQUES

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Market size and forecast by country
4.3.5. Naked plasmid vector
4.3.6. Gene gun
4.3.7. Electroporation
4.3.8. Lipofection
4.3.9. Others

Chapter: 5 GENE THERAPY MARKET, BY GENE TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ANTIGEN

5.2.1. Market size and forecast
5.2.2. Market size and forecast by country

5.3. CYTOKINE

5.3.1. Market size and forecast
5.3.2. Market size and forecast, by country

5.4. TUMOR SUPPRESSOR

5.4.1. Market size and forecast
5.4.2. Market size and forecast, by country

5.5. SUICIDE

5.5.1. Market size and forecast
5.5.2. Market size and forecast, by country

5.6. DEFICIENCY

5.6.1. Market size and forecast
5.6.2. Market size and forecast, by country

5.7. GROWTH FACTORS

5.7.1. Market size and forecast
5.7.2. Market size and forecast, by country

5.8. RECEPTORS

5.8.1. Market size and forecast
5.8.2. Market size and forecast, by country

5.9. OTHERS

5.9.1. Market size and forecast
5.9.2. Market size and forecast, by country

Chapter: 6 GENE THERAPY MARKET, BY APPLICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. ONCOLOGICAL DISORDERS

6.2.1. Market size and forecast
6.2.2. Market size and forecast, by country

6.3. RARE DISEASES

6.3.1. Market size and forecast
6.3.2. Market size and forecast, by country

6.4. CARDIOVASCULAR DISEASES

6.4.1. Market size and forecast
6.4.2. Market size and forecast, by country

6.5. NEUROLOGICAL DISORDERS

6.5.1. Market size and forecast
6.5.2. Market size and forecast, by country

6.6. INFECTIOUS DISEASES

6.6.1. Market size and forecast
6.6.2. Market size and forecast, by country

6.7. OTHER DISEASES

6.7.1. Market size and forecast
6.7.2. Market size and forecast, by country

Chapter: 7 GENE THERAPY MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast, by country
7.2.4. Market size and forecast, by vector type
7.2.5. Market size and forecast, by gene type
7.2.6. Market size and forecast, by application

7.2.6.1. U.S. market size and forecast, by vector type
7.2.6.2. U.S. market size and forecast, by gene type
7.2.6.3. U.S. market size and forecast, by application
7.2.6.4. Canada market size and forecast, by vector type
7.2.6.5. Canada market size and forecast, by gene type
7.2.6.6. Canada market size and forecast, by application
7.2.6.7. Mexico market size and forecast, by vector type
7.2.6.8. Mexico market size and forecast, by gene type
7.2.6.9. Mexico market size and forecast, by application

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast, by country
7.3.4. Market size and forecast, by vector type
7.3.5. Market size and forecast, by gene type
7.3.6. Market size and forecast, by application

7.3.6.1. Germany market size and forecast, by vector type
7.3.6.2. Germany market size and forecast, by gene type
7.3.6.3. Germany market size and forecast, by application
7.3.6.4. France market size and forecast, by vector type
7.3.6.5. France market size and forecast, by gene type
7.3.6.6. France market size and forecast, by application
7.3.6.7. UK market size and forecast, by vector type
7.3.6.8. UK market size and forecast, by gene type
7.3.6.9. UK market size and forecast, by application
7.3.6.10. Italy market size and forecast, by vector type
7.3.6.11. Italy market size and forecast, by gene type
7.3.6.12. Italy market size and forecast, by application
7.3.6.13. Spain market size and forecast, by vector type
7.3.6.14. Spain market size and forecast, by gene type
7.3.6.15. Spain market size and forecast, by application
7.3.6.16. Rest of Europe market size and forecast, by vector type
7.3.6.17. Rest of Europe market size and forecast, by gene type
7.3.6.18. Rest of Europe market size and forecast, by application

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast, by country
7.4.4. Market size and forecast, by vector type
7.4.5. Market size and forecast, by gene type
7.4.6. Market size and forecast, by application

7.4.6.1. Japan market size and forecast, by vector type
7.4.6.2. Japan market size and forecast, by gene type
7.4.6.3. Japan market size and forecast, by application
7.4.6.4. China market size and forecast, by vector type
7.4.6.5. China market size and forecast, by gene type
7.4.6.6. China market size and forecast, by application
7.4.6.7. India market size and forecast, by vector type
7.4.6.8. India market size and forecast, by gene type
7.4.6.9. India market size and forecast, by application
7.4.6.10. South Korea market size and forecast, by vector type
7.4.6.11. South Korea market size and forecast, by gene type
7.4.6.12. South Korea market size and forecast, by application
7.4.6.13. Rest of Asia-Pacific market size and forecast, by vector type
7.4.6.14. Rest of Asia-Pacific market size and forecast, by gene type
7.4.6.15. Rest of Asia-Pacific market size and forecast, by application

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast, by country
7.5.4. Market size and forecast, by vector type
7.5.5. Market size and forecast, by gene type
7.5.6. Market size and forecast, by application

7.5.6.1. Brazil market size and forecast, by vector type
7.5.6.2. Brazil market size and forecast, by gene type
7.5.6.3. Brazil market size and forecast, by application
7.5.6.4. South Africa market size and forecast, by vector type
7.5.6.5. South Africa market size and forecast, by gene type
7.5.6.6. South Africa market size and forecast, by application
7.5.6.7. Rest of LAMEA market size and forecast, by vector type
7.5.6.8. Rest of LAMEA market size and forecast, by gene type
7.5.6.9. Rest of LAMEA market size and forecast, by application

Chapter: 8 COMPANY PROFILE

8.1. ADAPTIMMUNE THERAPEUTICS PLC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. BIOCANCELL LTD.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio

8.3. BLUEBIRD BIO, INC.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments

8.4. CELGENE CORPORATION

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments

8.5. GILEAD SCIENCES, INC.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. GLAXOSMITHKLINE PLC

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. MERCK & CO., INC.

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. NOVARTIS AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. ONCOGENEX PHARMACEUTICALS, INC.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments

8.10. SPARK THERAPEUTICS, INC.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments

8.11. ABEONA THERAPEUTICS INC.

8.11.1. Company overview
8.11.2. Company snapshot
8.11.3. Operating business segments
8.11.4. Product portfolio
8.11.5. Business performance
8.11.6. Key strategic moves and developments

8.12. ADVERUM BIOTECHNOLOGIES, INC.

8.12.1. Company overview
8.12.2. Company snapshot
8.12.3. Operating business segments
8.12.4. Product portfolio
8.12.5. Key strategic moves and developments

8.13. APPLIED GENETIC TECHNOLOGIES CORPORATION

8.13.1. Company overview
8.13.2. Company snapshot
8.13.3. Operating business segments
8.13.4. Product portfolio
8.13.5. Key strategic moves and developments

8.14. ARBUTUS BIOPHARMA CORPORATION

8.14.1. Company overview
8.14.2. Company snapshot
8.14.3. Product portfolio
8.14.4. Business performance
8.14.5. Key strategic moves and developments

8.15. AUDENTES THERAPEUTICS INC.

8.15.1. Company overview
8.15.2. ompany snapshot
8.15.3. Product portfolio
8.15.4. Key strategic moves and developments

8.16. AVEXIS INC.

8.16.1. Company overview
8.16.2. Company snapshot
8.16.3. Product portfolio
8.16.4. Key strategic moves and developments

8.17. BLUEBIRD BIO, INC.

8.17.1. Company overview
8.17.2. Company snapshot
8.17.3. Operating business segments
8.17.4. Product portfolio
8.17.5. Business performance
8.17.6. Key strategic moves and developments

8.18. CRISPR THERAPEUTICS AG

8.18.1. Company overview
8.18.2. Company snapshot
8.18.3. Product portfolio
8.18.4. Key strategic moves and developments

8.19. EDITAS MEDICINE, INC.

8.19.1. Company overview
8.19.2. Company snapshot
8.19.3. Product portfolio

8.20. INTELLIA THERAPEUTICS INC.

8.20.1. Company overview
8.20.2. Company snapshot
8.20.3. Product portfolio
8.20.4. Business performance

8.21. GILEAD SCIENCES, INC. (KITE PHARMA, INC.)

8.21.1. Company overview
8.21.2. Company snapshot
8.21.3. Operating business segments
8.21.4. Product portfolio
8.21.5. Business performance
8.21.6. Key strategic moves and developments

8.22. REGENXBIO, INC.

8.22.1. Company overview
8.22.2. Company snapshot
8.22.3. Product portfolio
8.22.4. Key strategic moves and developments

8.23. SANGAMO THERAPEUTICS, INC.

8.23.1. Company overview
8.23.2. Company snapshot
8.23.3. Operating business segments
8.23.4. Product portfolio
8.23.5. Business performance
8.23.6. Key strategic moves and developments

8.24. UNIQURE N. V.

8.24.1. Company overview
8.24.2. Company snapshot
8.24.3. Operation segments
8.24.4. Product portfolio
8.24.5. Business performance
8.24.6. Key strategic moves and developments

8.25. VOYAGER THERAPEUTICS, INC.

8.25.1. Company overview
8.25.2. Company snapshot
8.25.3. Operating business segments
8.25.4. Product portfolio
8.25.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 2. GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2016-2023 ($MILLION)
TABLE 4. GENE THERAPY MARKET FOR NONVIRAL VECTORS, BY REGION, 2016-2023 ($MILLION)
TABLE 5. GLOBAL GENE THERAPY MARKET FOR NONVIRAL VECTORS, BY TYPE, 2016-2023 ($MILLION)
TABLE 6. GLOBAL GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 7. ANTIGEN GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 8. CYTOKINE GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 9. TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. SUICIDE GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. DEFICIENCY GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. GROWTH FACTORS GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 13. RECEPTORS GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GENE THERAPY MARKET FOR OTHER GENE TYPE, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 16. GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. GENE THERAPY MARKET FOR RARE DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 18. GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 19. GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2016-2023 ($MILLION)
TABLE 20. GENE THERAPY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 21. GENE THERAPY MARKET FOR OTHER DISEASES, BY REGION, 2016-2023 ($MILLION)
TABLE 22. GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 27. U.S. GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 28. U.S. GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 29. U.S. GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 30. CANADA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 31. CANADA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 32. CANADA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. MEXICO GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 34. MEXICO GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 35. MEXICO GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. EUROPE GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 37. EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 38. EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 39. EUROPE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 40. GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 41. GERMANY GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 42. GERMANY GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 44. FRANCE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 45. FRANCE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46. UK GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 47. UK GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 48. UK GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 49. ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 50. ITALY GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 51. ITALY GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 52. SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 53. SPAIN GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 54. SPAIN GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 55. REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 56. REST OF EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 57. REST OF EUROPE GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 58. ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 59. ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 60. ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 61. ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 62. JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 63. JAPAN GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 64. JAPAN GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 65. CHINA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 66. CHINA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 67. CHINA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 68. INDIA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 69. INDIA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 70. INDIA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 71. SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 72. SOUTH KOREA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 73. SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 75. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 76. REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 77. LAMEA GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 78. LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 79. LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 80. LAMEA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 81. BRAZIL GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 82. BRAZIL GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 83. BRAZIL GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 84. SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 85. SOUTH AFRICA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 86. SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 87. REST OF LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2016-2023 ($MILLION)
TABLE 88. REST OF LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2016-2023 ($MILLION)
TABLE 89. REST OF LAMEA GENE THERAPY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 90. ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY SNAPSHOT
TABLE 91. ADAPTIMMUNE THERAPEUTICS PLC.: BUSINESS UNIT
TABLE 92. ADAPTIMMUNE THERAPEUTICS PLC.: PRODUCT PORTFOLIO
TABLE 93. BIOCANCELL LTD.: COMPANY SNAPSHOT
TABLE 94. BIOCANCELL LTD.: PRODUCT CATEGORY
TABLE 95. BIOCANCELL LTD.: PRODUCT PORTFOLIO
TABLE 96. BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
TABLE 97. BLUEBIRD BIO, INC.: PRODUCT CATEGORY
TABLE 98. CELGENE CORPORATION: COMPANY SNAPSHOT
TABLE 99. CELGENE CORPORATION: OPERATING SEGMENTS
TABLE 100. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 101. GILEAD SCIENCES, INC.: OPERATING SEGMENTS
TABLE 102. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 103. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 104. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 105. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 106. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 107. MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 108. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 109. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 110. NOVARTIS AG : OPERATING DIVISION
TABLE 111. NOVARTIS AG : PRODUCT PORTFOLIO
TABLE 112. ONCOGENEX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 113. ONCOGENEX PHARMACEUTICALS, INC.: OPERATING SEGMENTS
TABLE 114. SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 115. SPARK THERAPEUTICS, INC.: PRODUCT CATEGORY
TABLE 116. SPARK THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 117. ABEONA THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE 118. ABEONA THERAPEUTICS INC.: PRODUCT CATEGORY
TABLE 119. ABEONA THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE 120. ADVERUM BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 121. ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT CATEGORY
TABLE 122. ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 123. APPLIED GENETIC TECHNOLOGIES CORPORATION: COMPANY SNAPSHOT
TABLE 124. APPLIED GENETIC TECHNOLOGIES CORPORATION: OPERATING SEGMENTS
TABLE 125. APPLIED GENETIC TECHNOLOGIES CORPORATION: PRODUCT PORTFOLIO
TABLE 126. ARBUTUS: COMPANY SNAPSHOT
TABLE 127. ARBUTUS: PRODUCT PORTFOLIO
TABLE 128. AUDENTES: COMPANY SNAPSHOT
TABLE 129. AUDENTES: PRODUCT PORTFOLIO
TABLE 130. AVEXIS: COMPANY SNAPSHOT
TABLE 131. AVEXIS: PRODUCT PORTFOLIO
TABLE 132. BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
TABLE 133. BLUEBIRD BIO, INC.: PRODUCT CATEGORY
TABLE 134. BLUEBIRD BIO, INC.: PRODUCT PORTFOLIO
TABLE 135. CRISPR: COMPANY SNAPSHOT
TABLE 136. CRISPR: PRODUCT PORTFOLIO
TABLE 137. EDITAS MEDICINE, INC.: COMPANY SNAPSHOT
TABLE 138. EDITAS MEDICINE: PRODUCT PORTFOLIO
TABLE 139. INTELLIA THERAPEUTICS: COMPANY SNAPSHOT
TABLE 140. INTELLIA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 141. GILEAD: COMPANY SNAPSHOT
TABLE 142. GILEAD SCIENCES, INC.: OPERATING SEGMENTS
TABLE 143. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 144. REGENXBIO INC.: COMPANY SNAPSHOT
TABLE 145. REGENXBIO INC.: PRODUCT PORTFOLIO
TABLE 146. SANGAMO THERAPEUTICS, INC. : COMPANY SNAPSHOT
TABLE 147. SANGAMO THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 148. SANGAMO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 149. UNIQURE N. V.: COMPANY SNAPSHOT
TABLE 150. UNIQURE N. V.: PRODUCT PORTFOLIO
TABLE 151. UNIQURE N. V.: PRODUCT PORTFOLIO
TABLE 152. VOYAGER THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 153. VOYAGER THERAPEUTICS, INC.: PRODUCT CATEGORIES
TABLE 154. VOYAGER THERAPEUTICS, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. GLOBAL GENE THERAPY MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS: BY GENE TYPE, 2016
FIGURE 3. TOP PLAYER POSITIONING, 2016
FIGURE 4. BARGAINING POWER OF BUYERS
FIGURE 5. BARGAINING POWER OF SUPPLIERS
FIGURE 6. THREAT OF NEW ENTRANTS
FIGURE 7. THREAT OF SUBSTITUTION
FIGURE 8. COMPETITIVE RIVALRY
FIGURE 9. RESTRAINTS AND DRIVERS: GLOBAL GENE THERAPY MARKET
FIGURE 10. COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR VIRAL VECTORS, 2016 VS 2023 ($MILLION)
FIGURE 11. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR NON-VIRAL VECTORS, 2016 VS 2023 (%)
FIGURE 12. COMPARATIVE REGIONAL ANALYSIS OF ANTIGEN GENE THERAPY MARKET, 2016 VS 2023 (%)
FIGURE 13. COMPARATIVE REGIONAL ANALYSIS OF CYTOKINE GENE THERAPY MARKET, 2016 VS 2023 (%)
FIGURE 14. COMPARATIVE REGIONAL ANALYSIS OF TUMOR SUPPRESSOR GENE THERAPY MARKET, 2016 VS 2023 (%)
FIGURE 15. COMPARATIVE REGIONAL ANALYSIS OF SUICIDE GENE THERAPY MARKET, 2016 VS 2023 (%)
FIGURE 16. COMPARATIVE REGIONAL ANALYSIS OF DEFICIENCY GENE THERAPY MARKET, 2016 VS 2023 (%)
FIGURE 17. COMPARATIVE REGIONAL ANALYSIS OF GROWTH FACTORS GENE THERAPY MARKET, 2016 VS 2023 (%)
FIGURE 18. COMPARATIVE REGIONAL ANALYSIS OF RECEPTORS GENE THERAPY MARKET, 2016 VS 2023 (%)
FIGURE 19. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR OTHER GENE TYPE, 2016 VS 2023 (%)
FIGURE 20. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, 2016 VS 2023 (%)
FIGURE 21. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR RARE DISEASES, 2016 VS 2023 (%)
FIGURE 22. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, 2016 VS 2023 (%)
FIGURE 23. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, 2016 VS 2023 (%)
FIGURE 24. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR INFECTIOUS DISEASES, 2016 VS 2023 (%)
FIGURE 25. COMPARATIVE REGIONAL ANALYSIS OF GENE THERAPY MARKET FOR OTHER DISEASES, 2016 VS 2023 (%)
FIGURE 26. ADAPTIMMUNE THERAPEUTICS PLC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 27. BLUEBIRD BIO, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 28. CELGENE CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 29. CELGENE CORPORATION: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 30. CELGENE CORPORATION: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 31. GILEAD SCIENCES, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 32. GILEAD SCIENCES, INC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 33. GLAXOSMITHKLINE PLC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 34. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 35. GLAXOSMITHKLINE PLC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 36. MERCK & CO., INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 37. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 38. MERCK & CO., INC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 39. NOVARTIS AG: REVENUE, 2015-2017 ($MILLION)
FIGURE 40. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. NOVARTIS AG: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. ONCOGENEX PHARMACEUTICALS, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 43. SPARK THERAPEUTICS, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 44. ABEONA THERAPEUTICS INC.: NET SALES, 2014-2016 ($MILLION)
FIGURE 45. ARBUTUS: NET SALES, 2014-2016 ($MILLION)
FIGURE 46. BLUEBIRD BIO, INC.: NET SALES, 2014-2016 ($MILLION)
FIGURE 47. INTELLIA THERAPEUTICS: NET SALES, 2015-2016 ($MILLION)
FIGURE 48. GILEAD: NET SALES, 2015-2017 ($MILLION)
FIGURE 49. GILEAD: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 50. SANGAMO THERAPEUTICS, INC.: NET SALES, 2015-2017 ($MILLION)
FIGURE 51. UNIQURE N. V.: NET SALES, 2014-2016 ($MILLION)

 

Over the recent years, the demand for gene therapy is on a rapid increase. With the advancement in technology, the gene therapy market has transformed during the recent few years. Gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Due to the high success rate during the preclinical and clinical trial, gene therapy is gaining popularity. There are many techniques used for gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of gene whose function is abnormal.

Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is on an increase, despite the limited number of products that have successfully reached the market. In addition, benefits of gene therapy over conventional cancer therapies and increase in government support fuel the growth of the gene therapy market.

Tumor suppressor and suicide gene therapy are expected to be a lucrative segment for the market players as they are among the fastest growing segment in the gene therapy market. The therapy involves the introduction of new genes into the tumor cells that help destroy the tumor cells without affecting the neighboring healthy cells.

The employment of gene therapy is highest in North America, owing to the increase in funding for the R&D activities, high prevalence rate of cancer, and increase in disposable income among customers. Although the use of gene therapy in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase due to rise in disposable income, rise in incidence rate of cancer, large number of clinical trials being conducted in these regions, and government initiative to improve healthcare infrastructure, which in turn fuel the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Gene Therapy Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo